ClinicalTrials.gg
Active, not recruitingNCT06676319AIRLYMPUSUpdated Sep 22, 2026

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

A Phase 2 interventional study of Lunsekimig and Short-Acting Beta Agonists (SABA) in Asthma, sponsored by Sanofi. Active, not recruiting at 221 sites in 22 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
556
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Asthma by Sanofi — 3 open to participants now, 5 under way, 1 of them phase 3. Asthma · Sanofi.

Enrollment
13th of 31
556 · median 450
Started
2024
with 2 others
Phase 2
11 of 37
1 open now
Registered
36th of 37
by date

Among the 37 studies in Asthma by Sanofi, this one is the 13th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2024, is one of 11 in phase 2, and was the 36th registered.

Asthma

4,849 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 37 studies in Asthma by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 416 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Asthma by Sanofi, or all of them as a file.
02

Study summary

This is a parallel-group, Phase 2, randomized, double-blind, placebo-controlled, 2-arm study for the treatment of asthma.

The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with subcutaneous (SC) lunsekimig compared with placebo in male and female participants (aged 18 to 80 years, inclusive) with asthma, who are not currently eligible for biologic treatments.

Study details include:

  • The study duration will be approximately 64 weeks for participants not transitioning into the LTS study and approximately 60 weeks for participants transitioning into the LTS study.
  • The investigational treatment duration will be up to approximately 52 weeks.
  • The number of visits will be 18.
03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Physician-diagnosed mild-to-moderate asthma for more than 12 months based on GINA guidelines.
  • At least 1 asthma exacerbation in the year prior to Screening (Visit 1).
  • Pre-BD of equal or more than 40% of predicted normal (by Global Lung Function Initiative [GLI] standards) at Screening (Visit 1).

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Other severe lung diseases (eg, [COPD]. bronchiectasis, idiopathic pulmonary fibrosis, etc) which may impair lung function.
  • Participants who experience a deterioration of asthma that results in emergency treatment or hospitalization, or treatment with systemic within 1 month prior to the Screening (Visit 1) (counting from the date of completion of treatment for asthma exacerbation).
  • Participants who have experienced an upper or lower respiratory tract infection within the 4 weeks prior to Screening (Visit 1).
  • Known history of, or suspected, significant current , including history of invasive opportunistic or helminthic infections despite infection resolution or otherwise recurrent infections of abnormal frequency or prolonged duration.
  • Evidence of any infection requiring systemic anti-infective treatment within 2 weeks before Screening (Visit 1) or during the screening period. Significant viral infections within 2 weeks before Screening (Visit 1) or during the screening period even if the participant has not received systemic antiviral treatment (eg, influenza receiving only symptomatic treatment).
  • Participants with active tuberculosis (TB), latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection, or who are at high risk of contracting TB (such as close contact with individuals with active TB), or received Bacillus Calmette-Guérin (BCG)-vaccination within 12 weeks prior to Screening (Visit 1).
  • Severe concomitant illness that would in the Investigator's opinion inhibit the participant's participation in the study, including for example, but not limited to, hypertension, renal disease, neurological conditions, heart failure, and pulmonary disease.

NOTE: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical study.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
556 participants (actual)

Study arms

  • Experimental
    Lunsekimig

    Participants will receive lunsekimig (SC injection) every 4 weeks

    Drug: Lunsekimig · Drug: Short-Acting Beta Agonists (SABA) · Drug: Fluticasone/Salmeterol · Drug: Budesonide/Formoterol · Drug: Budesonide/Albuterol

  • Placebo comparator
    Placebo

    Participants will receive placebo (SC injection) every 4 weeks

    Drug: Short-Acting Beta Agonists (SABA) · Drug: Placebo · Drug: Fluticasone/Salmeterol · Drug: Budesonide/Formoterol · Drug: Budesonide/Albuterol

Interventions

  • Pharmaceutical form: Solution for injection in vial; Route of administration: Subcutaneous injection

    Also known as: SAR443765

  • DrugShort-Acting Beta Agonists (SABA)

    Pharmaceutical form: Varies and depends on pharmaceutical presentation; Route of administration: Oral Inhalation

  • DrugPlacebo

    Pharmaceutical form: Solution for injection in vial; Route of administration: Subcutaneous injection

  • DrugFluticasone/Salmeterol

    Drug pages: Fluticasone · Salmeterol Xinafoate

    Pharmaceutical form: Varies and depends on pharmaceutical presentation; Route of administration:Oral Inhalation

  • DrugBudesonide/Formoterol

    Drug pages: Budesonide · Formoterol

    Pharmaceutical form: Varies and depends on pharmaceutical presentation; Route of administration: Oral Inhalation

  • DrugBudesonide/Albuterol

    Drug pages: Budesonide · Albuterol

    Pharmaceutical form: Aerosol for inhalation; Route of administration: Oral Inhalation

06

What researchers measure

Primary outcomes

  1. Annualized rate of asthma exacerbation events

    Asthma exacerbation event defined as: worsening of asthma requiring the use of systemic corticosteroids for ≥3 days; or hospitalization or emergency room visit due to asthma and requiring the use of systemic corticosteroids or death due to asthma

    Time frame: From baseline up to 52 weeks

Secondary outcomes

  1. Change from baseline in prebronchodilator (BD) forced expiratory volume in 1 second (FEV1)

    Time frame: From baseline to week 52

  2. Change from baseline in Asthma Control Questionnaire5 (ACQ-5) score

    The ACQ-5 is a questionnaire that measures the adequacy of asthma control and any changes in asthma control that may occur spontaneously or as a result of treatment. The ACQ-5 has five questions on the asthma symptoms and patients are asked to recall how their asthma has been during the previous week and to respond on a 7-point scale for each question (0 = no impairment, 6 = maximum impairment). The ACQ-5 score is the mean of the 5 questions and, therefore, between 0 (totally controlled) and 6 (severely uncontrolled). A high score indicates low asthma control.

    Time frame: From baseline to week 52

  3. Change from baseline in FeNO level

    Time frame: From baseline to week 52

  4. Annualized rate of loss of asthma control events (LOAC) events

    Annualized rate of LOAC events defined by 1 or more of the following criteria: * ≥30% reduction from baseline in morning PEF on 2 consecutive days * ≥6 additional reliever puffs of SABA in a 24-hour period (compared to baseline) on 2 consecutive days OR ≥4 additional puffs of low-dose budesonide/formoterol or budesonide/albuterol in a 24-hour period (compared to baseline) on 2 consecutive days * Worsening of asthma requiring the use of systemic corticosteroids for ≥3 days * Hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids (asthma exacerbation event) * Death due to asthma

    Time frame: From baseline to week 52

  5. Annualized rate of asthma exacerbations requiring hospitalization or emergency room or urgent care visit

    Time frame: From baseline to week 52

  6. Total systemic corticosteroid dose exposure

    Time frame: From baseline to week 52

  7. Change from baseline in Asthma Quality of Life Questionnaire Standardized (AQLQ{S}) scores

    Time frame: From baseline to week 52

  8. Change from baseline in the Asthma Daytime Symptom Diary (ADSD) daily morning and evening score

    Time frame: From baseline to week 52

  9. Serum lunsekimig concentrations

    Time frame: From baseline to week 56

  10. Incidence and titer of anti-drug antibodies (ADA) against lunsekimig

    Time frame: From baseline to week 56

  11. Incidence of participants with treatment-emergent adverse events (TEAEs), including local reactions, adverse events of special interests (AESIs), serious adverse events (SAEs)

    Time frame: From baseline to week 56

07

Study locations

221 sites
  • The Center for Clinical Trials - Saraland- Site Number : 8400096
    Saraland, Alabama 36571, United States
  • Chandler Clinical Research Trials- Site Number : 8400075
    Chandler, Arizona 85224, United States
  • Epic Medical Research - Sun City- Site Number : 8400052
    Sun City, Arizona 85351, United States
  • Tucson Clinical Research Institute- Site Number : 8400085
    Tucson, Arizona 85712, United States
  • Ark Clinical Research- Site Number : 8400097
    Long Beach, California 90815, United States
  • Downtown L.A. Research Center- Site Number : 8400080
    Los Angeles, California 90017, United States
  • Carbon Health - North Hollywood - NoHo West- Site Number : 8400061
    North Hollywood, California 91606, United States
  • Carbon Health - San Mateo - Hillsdale Mall- Site Number : 8400062
    San Mateo, California 94403, United States
  • Stanford University Medical Center- Site Number : 8400108
    Stanford, California 94305, United States
  • Modena Allergy And Asthma- Site Number : 8400068
    Torrance, California 90505, United States
  • Howard University Hospital- Site Number : 8400107
    Washington D.C., District of Columbia 20060, United States
  • Helix Biomedics- Site Number : 8400005
    Boynton Beach, Florida 33435, United States
  • Beautiful Minds Clinical Research Center- Site Number : 8400019
    Cutler Bay, Florida 33157, United States
  • Omega Research Consultants - Debary - North Charles Richard Beall Boulevard- Site Number : 8400082
    DeBary, Florida 32713, United States
  • Alfa Medical Research- Site Number : 8400071
    Hollywood, Florida 33024, United States
  • Royal Clinical Trials - Inverness- Site Number : 8400067
    Inverness, Florida 34453, United States
  • Premier Medical Associates- Site Number : 8400077
    Lady Lake, Florida 32159, United States
  • D&H Pompano Research Center- Site Number : 8400072
    Margate, Florida 33063, United States
  • Research Institute of South Florida- Site Number : 8400023
    Miami, Florida 33173, United States
  • Innovations Biotech- Site Number : 8400044
    Miami, Florida 33186, United States
  • Tellabio International Research Services- Site Number : 8400083
    Pembroke Pines, Florida 33025, United States
  • Avanza Medical Research Center- Site Number : 8400056
    Pensacola, Florida 32503, United States
  • Ilumina Medical Research- Site Number : 8400095
    Saint Cloud, Florida 34769, United States
  • Private Practice - Dr. David Kavtaradze- Site Number : 8400081
    Cordele, Georgia 31015, United States
  • EmVenio Research - Riverdale- Site Number : 8400109
    Riverdale, Georgia 30274, United States
  • Christie Clinic in Champaign on University- Site Number : 8400003
    Champaign, Illinois 61820, United States
  • University of Kansas Medical Center- Site Number : 8400105
    Kansas City, Kansas 66160, United States
  • Velocity Clinical Research - Rockville (formerly Meridian Clinical Research)- Site Number : 8400036
    Rockville, Maryland 20854, United States
  • Javara - Privia Medical Group - Silver Spring Lockwood- Site Number : 8400042
    Silver Spring, Maryland 20901, United States
  • University of Michigan Health System - Ann Arbor- Site Number : 8400014
    Ann Arbor, Michigan 48109, United States
  • Clarkston Medical Group- Site Number : 8400054
    Clarkston, Michigan 48346, United States
  • Javara - Mankato Clinic- Site Number : 8400001
    Mankato, Minnesota 56001, United States
  • Mayo Clinic in Rochester - Minnesota- Site Number : 8400057
    Rochester, Minnesota 55905, United States
  • Hannibal Regional Healthcare System- Site Number : 8400078
    Hannibal, Missouri 63401, United States
  • Icahn School of Medicine at Mount Sinai (ISMMS) - Mount Sinai Doctors- Site Number : 8400069
    New York, New York 10011, United States
  • Pioneer Clinical Research - New York- Site Number : 8400092
    New York, New York 10016, United States
  • Piedmont Healthcare - Family Medicine- Site Number : 8400064
    Statesville, North Carolina 28625, United States
  • Cleveland Clinic - Cleveland- Site Number : 8400106
    Cleveland, Ohio 44195, United States
  • Asthma & Allergy Center - Toledo- Site Number : 8400020
    Toledo, Ohio 43617, United States
  • OK Clinical Research- Site Number : 8400060
    Edmond, Oklahoma 73034, United States
  • Clinical Research Associates of Central Pennsylvania- Site Number : 8400013
    DuBois, Pennsylvania 15801, United States
  • Thomas Jefferson University Hospital- Site Number : 8400110
    Philadelphia, Pennsylvania 19107, United States
  • Allergic Disease and Asthma Center (ADAC)- Site Number : 8400070
    Greenville, South Carolina 29607, United States
  • Orion Clinical Research- Site Number : 8400084
    Austin, Texas 78759, United States
  • South Texas Medical Research Institute - TTS Research- Site Number : 8400015
    Boerne, Texas 78006, United States
  • Epic Medical Research - De Soto- Site Number : 8400051
    DeSoto, Texas 75115, United States
  • Axsendo Clinical Research - Houston- Site Number : 8400065
    Houston, Texas 77058, United States
  • Metroplex Pulmonary and Sleep Center- Site Number : 8400012
    McKinney, Texas 75069, United States
  • STAAMP Research - San Antonio- Site Number : 8400059
    San Antonio, Texas 78229, United States
  • Bandera Family Health Care - San Antonio- Site Number : 8400049
    San Antonio, Texas 78249, United States
  • Javara - San Marcos - Redwood Road- Site Number : 8400040
    San Marcos, Texas 78666, United States
  • Simcare Medical Research- Site Number : 8400102
    Sugar Land, Texas 77478, United States
  • Children's Wisconsin- Site Number : 8400073
    Milwaukee, Wisconsin 53226, United States
  • Investigational Site Number : 0320007
    Berazategui, Buenos Aires 1886, Argentina
  • Investigational Site Number : 0320013
    Lobos, Buenos Aires 7240, Argentina
  • Investigational Site Number : 0320006
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320010
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320016
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320003
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Investigational Site Number : 0320005
    Buenos Aires, 1121, Argentina
  • Investigational Site Number : 0320012
    Buenos Aires, 1122, Argentina
  • Investigational Site Number : 0320002
    Buenos Aires, 1414, Argentina
  • Investigational Site Number : 0320001
    Buenos Aires, 1425, Argentina
  • Investigational Site Number : 0320004
    Buenos Aires, 1425, Argentina
  • Investigational Site Number : 0320008
    Corrientes, 3400, Argentina
  • Investigational Site Number : 0320011
    La Plata, Buenos Aires, B1904CUL, Argentina
  • Investigational Site Number : 0320014
    Mendoza, 5500, Argentina
  • Investigational Site Number : 0320015
    Mendoza, 5500, Argentina
  • Investigational Site Number : 0320009
    Santa Fe, 3000, Argentina
  • Investigational Site Number : 0560003
    Liège, 4000, Belgium
  • Investigational Site Number : 0560002
    Mechelen, 2800, Belgium
  • Associacao Proar- Site Number : 0760002
    Salvador, Estado de Bahia 40060-330, Brazil
  • Universidade Federal de Goias- Site Number : 0760011
    Goiânia, Goiás 74605-020, Brazil
  • Hospital de Clinicas da Universidade Federal do Parana- Site Number : 0760006
    Curitiba, Paraná 80060-900, Brazil
  • Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760001
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • WM Pesquisas Clínicas em Doenças Respiratórias- Site Number : 0760003
    Porto Alegre, Rio Grande do Sul 91010-006, Brazil
  • Incor - Instituto do Coracao- Site Number : 0760004
    São Paulo, 05403-000, Brazil
  • Investigational Site Number : 1240011
    Kelowna, British Columbia V1Y 4N7, Canada
  • Investigational Site Number : 1240012
    West Vancouver, British Columbia V7T 2Z3, Canada
  • Investigational Site Number : 1240013
    Ajax, Ontario L1S 2J5, Canada
  • Investigational Site Number : 1240003
    Guelph, Ontario N1h 6j2, Canada
  • Investigational Site Number : 1240006
    Stoney Creek, Ontario L8G 2V6, Canada
  • Investigational Site Number : 1240008
    Toronto, Ontario M4G 3E8, Canada
  • Investigational Site Number : 1240014
    Montreal, Quebec H2X 3E4, Canada
  • Investigational Site Number : 1240002
    Sherbrooke, Quebec J1H 5N4, Canada
  • Investigational Site Number : 1520008
    Concepción, Biobio 4070094, Chile
  • Investigational Site Number : 1520002
    Talca, Maule Region 3465584, Chile
  • Investigational Site Number : 1520009
    Lo Barnechea, Reg Metropolitana de Santiago 7691236, Chile
  • Investigational Site Number : 1520010
    Recoleta, Reg Metropolitana de Santiago 8420000, Chile
  • Investigational Site Number : 1520006
    Santiago, Reg Metropolitana de Santiago 7500587, Chile
  • Investigational Site Number : 1520001
    Santiago, Reg Metropolitana de Santiago 7500692, Chile
  • Investigational Site Number : 1520003
    Santiago, Reg Metropolitana de Santiago 7500698, Chile
  • Investigational Site Number : 1520005
    Quillota, Valparaiso 2260877, Chile
  • Investigational Site Number : 1520004
    Viña del Mar, Valparaiso 2531172, Chile
  • Investigational Site Number : 1520007
    Viña del Mar, Valparaiso 2540364, Chile
  • Investigational Site Number : 1560027
    Beijing, 100029, China
  • Investigational Site Number : 1560005
    Changchun, 130021, China
  • Investigational Site Number : 1560021
    Chengde, 067020, China
  • Investigational Site Number : 1560039
    Chengdu, 611130, China
  • Investigational Site Number : 1560028
    Foshan, 528399, China

Showing the first 100 of 221 sites across 22 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jun 2027, 31 months after the start.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's planned 31 months is above that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2024
First posted
Nov 6, 2024
StartActual
Nov 7, 2024
Primary completionEst.
Jun 21, 2027
CompletionEst.
Jul 19, 2027
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06676319
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 6, 2024
Start date
Nov 7, 2024
Primary completion
Jun 21, 2027 (estimated)
Completion
Jul 19, 2027 (estimated)
Last update
Sep 22, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lunsekimig

Start the discussion